STOCKHOLM, Sept. 13, 2024 /PRNewswire/ — Moberg Pharma AB (OMX: MOB) announces that the company has received information about clinical cure in a subset of patients in the ongoing North American Phase 3 study for MOB-015 […]
Tag: Pharmaceuticals
TCI revolutioniert das Gewichtsmanagement mit bahnbrechender GLP-1-Innovation
TAIPEI, 12. September 2024 /PRNewswire/ — TCI Co. Ltd. („TCI”, 8436.TWO), seit über 40 Jahren ein weltweit führender Anbieter von ODM-Gesundheits- und Kosmetikprodukten, stellt seine innovative GLP-1-Formel vor, eine natürliche Mischung aus Pflanzenextrakten, Probiotika und Präbiotika, […]
BIOVAXYS ANNOUNCES CLOSING OF THIRD TRANCHE OF PRIVATE PLACEMENT
// NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES // VANCOUVER, BC, Sept. 11, 2024 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (“BioVaxys” or the “Company“) […]
Innovent’s Phase 3 Clinical Trial DREAMS-2 of Mazdutide in Chinese Patients with Type 2 Diabetes were Orally Presented at EASD 2024
SAN FRANCISCO and SUZHOU, China, Sept. 11, 2024 /PRNewswire/ — Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and […]
TREMFYA® (guselkumab) receives U.S. FDA approval for adults with moderately to severely active ulcerative colitis, strengthening Johnson & Johnson’s leadership in inflammatory bowel disease
The first and only dual-acting interleukin-23 inhibitor approved in active ulcerative colitis, TREMFYA® showed highly statistically significant rates of endoscopic remission at one year in the pivotal QUASAR program1,2,3,4,5 TREMFYA® is now approved for the treatment of […]
